Acucela Doses First Subject in Phase I Trial for Age-Related Macular Degeneration
News Jun 04, 2008
Acucela Inc. has announced that it has dosed the first subject in a Phase I trial for its lead compound ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of ACU-02.
ACU-02 is an orally available small molecule being developed for the treatment of the dry form of age-related macular degeneration (AMD).
ACU-02 is a potent modulator of the visual cycle that acts by interrupting the pathophysiology of AMD by significantly reducing the accumulation of the retinal related toxic by-product A2E which is believed to damage retinal cells, thus leading to the decrease or loss of vision in AMD patients.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE